Evidence map›Paper›PMID 26657200›Full record

ArticleBlood cancer journal2015

Prediction of response and survival in patients with chronic-phase chronic myeloid leukemia treated with omacetaxine mepesuccinate: logistic regression and landmark analyses.

M Wetzler, H M Kantarjian, F E Nicolini, J H Lipton, L Akard, M Baccarani, H J Khoury, E Li, M Munteanu, J Cortes

Abstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in Blood cancer journal, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

M WetzlerRoswell Park Cancer Institute, Leukemia Section, Buffalo, NY, USA.
H M KantarjianDepartment of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
F E NicoliniDepartment of Hematology, Centre Hospitalier Lyon Sud, Pierre Bénite, France.
J H LiptonPrincess Margaret Cancer Centre, Allogeneic Blood and Marrow Transplant Program, Toronto, Ontario, Canada.
L AkardIndiana Blood and Marrow Transplantation, Hematology, Indianapolis, IN, USA.
M BaccaraniUniversity of Bologna, Institute of Hematology and Medical Oncology, Bologna, Italy.
H J KhouryDepartment of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, USA.
E LiPharmaStat LLC, Newark, CA, USA.
M MunteanuTeva Branded Pharmaceutical Products R&D, Clinical Development, Frazer, PA, USA.
J CortesDepartment of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Antineoplastic Agents, PhytogenicDrug Resistance, NeoplasmHarringtoninesHomoharringtonineHumansLeukemia, Myelogenous, Chronic, BCR-ABL PositiveRegression AnalysisSurvival AnalysisAntineoplastic Agents, PhytogenicHarringtoninesHomoharringtonine

Identifiers

PMID26657200
PMCPMC4735071

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.